National Bank of Canada FI Acquires 863,216 Shares of Amgen Inc. $AMGN

National Bank of Canada FI raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 237.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,226,372 shares of the medical research company’s stock after purchasing an additional 863,216 shares during the quarter. National Bank of Canada FI’s holdings in Amgen were worth $346,076,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Brighton Jones LLC grew its stake in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares during the period. Schnieders Capital Management LLC. lifted its position in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after acquiring an additional 5,853 shares during the last quarter. Citizens Financial Group Inc. RI boosted its holdings in shares of Amgen by 63.9% during the second quarter. Citizens Financial Group Inc. RI now owns 15,668 shares of the medical research company’s stock worth $4,375,000 after acquiring an additional 6,110 shares during the period. Finally, Alberta Investment Management Corp bought a new stake in shares of Amgen during the second quarter worth approximately $474,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Up 0.0%

Shares of AMGN opened at $366.25 on Tuesday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The firm’s 50 day moving average is $358.64 and its 200-day moving average is $326.25. The stock has a market capitalization of $197.43 billion, a PE ratio of 25.74, a P/E/G ratio of 3.63 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Mizuho increased their target price on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Rothschild & Co Redburn boosted their price target on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Daiwa Securities Group upped their price objective on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Guggenheim increased their price objective on Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $354.00.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.